These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25470699)

  • 61. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M; De Marinis F; Hirsch FR; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.
    Guérin A; Sasane M; Wakelee H; Zhang J; Culver K; Dea K; Nitulescu R; Galebach P; Macalalad AR
    Curr Med Res Opin; 2015 Aug; 31(8):1587-97. PubMed ID: 26029864
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT; Solomon B
    Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment and detection of ALK-rearranged NSCLC.
    Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
    Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.
    Juan O; Popat S
    Lung Cancer; 2017 Feb; 104():131-133. PubMed ID: 27863911
    [No Abstract]   [Full Text] [Related]  

  • 66. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.
    Browning ET; Weickhardt AJ; Camidge DR
    J Thorac Oncol; 2013 Mar; 8(3):e21. PubMed ID: 23407562
    [No Abstract]   [Full Text] [Related]  

  • 68. Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data.
    Toyokawa G; Seto T
    Oncol Res Treat; 2015; 38(6):291-8. PubMed ID: 26045026
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.
    Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
    J Clin Oncol; 2016 Oct; 34(28):3383-9. PubMed ID: 27354483
    [TBL] [Abstract][Full Text] [Related]  

  • 70. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K
    J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
    [No Abstract]   [Full Text] [Related]  

  • 71. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.
    Godbert Y; Henriques de Figueiredo B; Bonichon F; Chibon F; Hostein I; Pérot G; Dupin C; Daubech A; Belleannée G; Gros A; Italiano A; Soubeyran I
    J Clin Oncol; 2015 Jul; 33(20):e84-7. PubMed ID: 24687827
    [No Abstract]   [Full Text] [Related]  

  • 72. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
    J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
    Caccese M; Ferrara R; Pilotto S; Carbognin L; Grizzi G; Caliò A; Brunelli M; Cuppone F; Petraglia S; Scarpa A; Tortora G; Bria E
    Expert Opin Pharmacother; 2016 Dec; 17(17):2253-2266. PubMed ID: 27682212
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G; Seto T; Takenoyama M; Ichinose Y
    Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selpercatinib Receives Regular Approval for Non-Small Cell Lung Cancer.
    Larkin HD
    JAMA; 2022 Nov; 328(17):1679. PubMed ID: 36318150
    [No Abstract]   [Full Text] [Related]  

  • 76. Personalized one-two punches for lung cancer.
    Scarborough HA; Bunn PA; DeGregori J
    Cell Res; 2015 Mar; 25(3):269-70. PubMed ID: 25547118
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapeutics: Winning combination.
    Villanueva MT
    Nat Rev Cancer; 2015 Jan; 15(1):2. PubMed ID: 25533666
    [No Abstract]   [Full Text] [Related]  

  • 78. Anticancer drugs: Finding the perfect combination.
    Flemming A
    Nat Rev Drug Discov; 2015 Jan; 14(1):13. PubMed ID: 25549585
    [No Abstract]   [Full Text] [Related]  

  • 79. Lung cancer: combating resistance through IGF-1R and ALK co-targeting.
    Hutchinson L
    Nat Rev Clin Oncol; 2014 Nov; 11(11):622. PubMed ID: 25223557
    [No Abstract]   [Full Text] [Related]  

  • 80. Treatment for early-stage lung cancer: what next?
    Paz-Ares L; Corral J
    Lancet; 2014 May; 383(9928):1528-30. PubMed ID: 24576775
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.